Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway

AIMS: Although extracellular-regulated kinases (ERK) are a well-known central mediator in cardiac hypertrophy, no clinically available ERK antagonist has been tested for preventing cardiac hypertrophy. Selumetinib is a novel oral MEK inhibitor that is currently under Phase II and Phase III clinical...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:PLoS One
Auteurs principaux: Li, Chen, Chen, Zhongxiu, Yang, Hao, Luo, Fangbo, Chen, Lihong, Cai, Huawei, Li, Yajiao, You, Guiying, Long, Dan, Li, Shengfu, Zhang, Qiuping, Rao, Li
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4954659/
https://ncbi.nlm.nih.gov/pubmed/27438013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0159079
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires